U.S. markets open in 2 hours 52 minutes
  • S&P Futures

    3,861.75
    +42.50 (+1.11%)
     
  • Dow Futures

    31,959.00
    +183.00 (+0.58%)
     
  • Nasdaq Futures

    12,594.50
    +297.25 (+2.42%)
     
  • Russell 2000 Futures

    2,235.80
    +35.00 (+1.59%)
     
  • Crude Oil

    65.69
    +0.64 (+0.98%)
     
  • Gold

    1,704.60
    +26.60 (+1.59%)
     
  • Silver

    25.89
    +0.62 (+2.44%)
     
  • EUR/USD

    1.1913
    +0.0061 (+0.51%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.38
    -0.28 (-1.14%)
     
  • GBP/USD

    1.3883
    +0.0062 (+0.45%)
     
  • USD/JPY

    108.6800
    -0.2210 (-0.20%)
     
  • BTC-USD

    53,997.86
    +3,838.76 (+7.65%)
     
  • CMC Crypto 200

    1,089.82
    +65.61 (+6.41%)
     
  • FTSE 100

    6,777.68
    +58.55 (+0.87%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Dec 3 (Reuters) - Japan's Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate, the U.S.-based vaccine maker said on Thursday.

It did not disclose the terms of the agreement with Kaneka Eurogentec, a unit of the Japanese chemical company.

Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others, to increase supply of the vaccine, which entered a mid-stage study last month.

The Phase 3 of the mid-to-late stage study is under a partial hold by the U.S. Food and Drug Administration as it seeks more information, including details on a delivery device used to inject genetic material into cells. (Reporting by Amruta Khandekar; Editing by Shinjini Ganguli)